Title: Effect of Single Dose Intravitreal Ranibizumab in Central Retinal Vein Occlusion: A Single Center Study
Authors: Dr Ashwini Meherda, Prof Dr Subhabrata Parida, Dr Deepak Choudhury, Dr Nikita Dash, Mr Akbar Mehfuz Alam
DOI: https://dx.doi.org/10.18535/jmscr/v7i7.52
Abstract
Aim: To find out outcome following single intravitreal injection of ranibizumab in central retinal vein occlusion (CRVO) patients in a government hospital in the capital of Odisha.
Methods: This study was a prospective interventional study of 18 months duration done from August 2017 to February 2019 included 15 cases of CRVO. Thorough history was taken and detail ophthalmological evaluation was done. Best corrected visual acuity (BCVA) was examined with Snellen’s chart and central macular thickness (CMT) was measured using optical coherence tomography (OCT). Routine blood tests were done. Intravitreal injection of ranibizumab 0.5 mg in 0.05 ml was given. BCVA and CMT was measured at 1 day, 1 week, 1 month and 3 month follow up visit.
Results: Mean age was 59.53 ± 8.65 years. Male: female ratio was 2.8:1. Diastolic blood pressure of ≥ 90 was found in 46.7% patients. 60% cases showed improvement at 1 week post-operatively.At post-operative day 1 CMT was significantly decreased (p= 0.0193). Reduction in mean CMT at post-operative day 7 was >290 µ.
Conclusion: Single intravitreal injection of ranibizumab 0.5 mg in 0.05 ml causes significant increase in vision and significant reduction of central macular thickness in patients with branch retinal vein occlusion.
Keyword: CRVO, ranibizumab, OCT.
References
1. Woo Y, Lip G, Lip P. Associations of retinal artery occlusion and retinal vein occlusion to mortality, stroke, and myocardial infarction: a systematic review. Eye. 2016 June; 30:1031-8.
- Lim L, Cheung N, Wang J, Islam F, Mitchell P, Saw S, Aung T, Wong T. Prevalence and risk factors of retinal vein occlusion in an Asian population. Br J Ophthalmol. 2008 Oct;92(10):1316-9.
- Cugati S, Wang J, Rochtchina E. Ten-year incidence of retinal vein occlusion in an older population the Blue Mountains eye study. Arch Ophthalmolol. May 2006; 124(5):726-32.
- Hayreh S, Klugman M, Beri M, Kimura A, Podhajsky P. Differentiation of ischemic from non-ischemic central retinal vein occlusion during the early acute phase. Graefes Arch. Clin. Exp. Ophthalmol. 1990;228(3):201-17.
- Baseline and early natural history report. The Central Vein Occlusion Study. Arch. Ophthalmol. 1993 Aug;111(8):1087-95.
- Klein R, Moss S, Meuer S, Klein B. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study. Arch. Ophthalmol. 2008 Apr;126 (4):513-8.
- Parodi MB, Bandello F. Branch retinal vein occlusion: classification and treatment. Ophthalmologica. 2009;223(5):298-305.
- Iturralde D, Spaide R, Meyerle C, Klancnik J, Yannuzzi L, Fisher Y et al. Intravitreal bevacizumab (Avastin) treatment of macular edema in central retinal vein occlusion: a short term study. Retina. 2006 Mar; 26(3): 279-84.
- Brown D, Campochiaro P, Singh R, Li Z, Gray S, Saroj N et al. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology. June 2010; 117(6): 1124-33.
- The Central Vein Occlusion Study Group. Natural history and clinical management of central retinal vein occlusion. Arch Ophthalmol. 1997 April; 115:486–91.